CA14

Carbonic anhydrase 14 · Q9ULX7 · CA14 on Sugi Atlas →

387,514 patent compounds predicted against CA14, 225,593 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Benzthiazide (SCHEMBL26257)	0.42	8/20
Benzenesulfonamide (SCHEMBL729)	1.00	7/20
Sulfanilamide (SCHEMBL740)	1.00	7/20
Coumarin (SCHEMBL6252)	1.00	7/20
SCHEMBL16810	0.42	7/20
SCHEMBL19256	0.34	7/20
SCHEMBL19257	0.34	7/20
2,4-Dihydroxybenzoic Acid (SCHEMBL28080)	1.00	6/20
Ethylparaben (SCHEMBL28368)	1.00	6/20
SCHEMBL19880	0.55	6/20
Benzthiazide (SCHEMBL26258)	0.42	6/20
Methylparaben (SCHEMBL4440)	1.00	5/20
Spermine (SCHEMBL14965)	1.00	5/20
Trientine (SCHEMBL15439)	1.00	5/20
Spermidine (SCHEMBL15618)	1.00	5/20
SCHEMBL15797	1.00	5/20
SCHEMBL26707	1.00	5/20
SCHEMBL28170	1.00	5/20
SCHEMBL20976	0.86	5/20
SCHEMBL26667	0.85	5/20

Clinical trials — most relevant to CA14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer	PHASE3	COMPLETED
Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC	PHASE2/PHASE3	RECRUITING
Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer	PHASE3	RECRUITING
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status	PHASE2	RECRUITING
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model	PHASE1/PHASE2	UNKNOWN
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy	PHASE2	RECRUITING
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies	PHASE2	WITHDRAWN
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer	PHASE2	RECRUITING
Immunotherapy of Cervical Cancer With V3-Cervix	PHASE2	UNKNOWN
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Serum Retinoic Acid Induced Protein 14 (RAI14) and Metastasis Associated Cancer Colon -1 (MACC-1) in Breast Cancer	nan	UNKNOWN
The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.	nan	COMPLETED
Analysis the Positive Rate of Tumor Markers Among Physical Examination Population	nan	COMPLETED
Detection of Plasma Circulating Tumor DNA in Gastric Cancer	nan	UNKNOWN
Post-operative Monitoring of Gastric Cancer	nan	RECRUITING
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis	nan	COMPLETED
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer	nan	UNKNOWN
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer	nan	UNKNOWN
The Etiology and Progression of Brain Tumors	nan	COMPLETED
Carbohydrate Antigen 19-9 in Colorectal Cancer	nan	UNKNOWN
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Risk of Ovarian Cancer in Patients With a Pelvic Mass	nan	COMPLETED
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer	nan	COMPLETED
Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome	nan	UNKNOWN
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer	nan	RECRUITING
Mesothelin as a New Tumor Marker for Ovarian Cancer	nan	UNKNOWN
Early Detection and Post-operative Monitoring of Gastric Cancer	nan	RECRUITING
Assessment of CA 19-9 in Patients' With Thyroid Malignancies	nan	UNKNOWN
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a CA14 binder may also engage these)

Protein	Name	Similarity
Q9WVT6	—	0.987	Q9WVT6 →
CA5A	Carbonic anhydrase 5A, mitochondrial	0.950	landscape →
Q8BG28	—	0.925	Q8BG28 →
P23589	—	0.924	P23589 →
ERBB2	Receptor tyrosine-protein kinase erbB-2	0.923	landscape →
Q6QNK2	—	0.922	Q6QNK2 →
Q8BQH6	—	0.921	Q8BQH6 →
CA5B	Carbonic anhydrase 5B, mitochondrial	0.921	landscape →
O18735	—	0.920	O18735 →
Q8CIW5	—	0.919	Q8CIW5 →
Q5RJL2	—	0.918	Q5RJL2 →
Q80T32	—	0.918	Q80T32 →
P43165	—	0.918	P43165 →
Q5VXM1	—	0.918	Q5VXM1 →
NOTUM	Palmitoleoyl-protein carboxylesterase NOTUM	0.917	landscape →
P26013	—	0.917	P26013 →
O88272	—	0.917	O88272 →
CHKB	Choline/ethanolamine kinase	0.916	landscape →
A6NDV4	—	0.916	A6NDV4 →
P97553	—	0.916	P97553 →
TRHDE	Thyrotropin-releasing hormone-degrading ectoenzyme	0.916	landscape →
Q8NCR0	—	0.916	Q8NCR0 →
F1NZI4	—	0.916	F1NZI4 →
O00292	—	0.916	O00292 →
Q9QZA0	—	0.916	Q9QZA0 →
Q66HG6	—	0.916	Q66HG6 →
P41271	—	0.916	P41271 →
J3S6Y1	—	0.916	J3S6Y1 →
Q10836	—	0.916	Q10836 →
Q06AS9	—	0.915	Q06AS9 →